One of the goals of the REMEDi4ALL projects is to develop an innovation platform supporting promising, high-impact drug repurposing projects championed by patients in any phase of development and disease area. To test the platform’s viability and robustness, we support four real-world projects on infectious diseases, rare cancers, and rare/ultra rare diseases.
COVID-19
Validation of drugs and combinations for novel host targets in SARS-CoV-2 infection.
MSD
Clinical PhI/II open label repurposing trial with tazarotene to assess safety/efficacy for treatment of multiple sulfatase deficiency (MSD) patients.
OI
Repurposing of losartan for treatment of Osteogenesis imperfecta (OI) patients.
PANCREATIC CANCER
Repurposing of valproic acid combined with simvastatin to potentiate first line gemcitabine/nab-paclitaxel chemotherapy regimen in metastatic pancreatic cancer (mPDAC) patients.
REMEDi4ALL Partners & Associated partners
